Cell and Gene Therapy Approval in Canada: What Health Canada's BGTD Pathway Actually Requires

Canada approved its first CAR-T cell therapy, Kymriah (tisagenlecleucel), in 2018. Since then, the pipeline has expanded considerably. The Alliance for Regenerative Medicine tracked more than 1,800 active clinical programs in cell, gene, and RNA therapy globally as of 2023, and Canada’s own clinical trial landscape is growing in step — driven partly by a strong academic research base and partly by the federal government’s increased investment in life sciences infrastructure.

But the regulatory path to Health Canada authorization for these products is genuinely unlike anything a traditional small-molecule or even conventional biologic sponsor has navigated before. The manufacturing challenges are different. The clinical trial authorization requirements are more demanding. And the assumptions sponsors carry in from US or European development programs often create friction — sometimes at exactly the wrong moment in a program timeline.

Here’s what you actually need to know before filing your first cell or gene therapy submission in Canada.

How Health Canada Classifies and Oversees Cell and Gene Therapy Products

Cell and gene therapies in Canada are regulated as biologic drugs under the Food and Drugs Act and fall under Part C, Division 4 of the Food and Drug Regulations. The primary reviewer is Health Canada’s Biologics and Genetic Therapies Directorate (BGTD), which sits within the Health Products and Food Branch (HPFB).

This is worth stating plainly because sponsors transitioning from the US often expect a structure that mirrors FDA’s Center for Biologics Evaluation and Research (CBER). The Canadian framework is similar in principle but not identical in practice — and the differences aren’t cosmetic.

For classification purposes, somatic cell therapy products (SCTPs), gene therapy products (including viral vector-based and nucleic acid therapies), and most engineered tissue products all fall under BGTD’s mandate. The key distinction driving review intensity is whether a product modifies the patient’s genetic material or introduces genetic material into cells. Gene therapy products — particularly those using integrating viral vectors — face the most rigorous characterization demands, with specific expectations around vector characterization, biodistribution studies, and germline integration risk assessment.

Health Canada formally adopted ICH S12 (Nonclinical Biodistribution Considerations for Gene Therapy Products) in 2023. This guideline now sets the standard for what preclinical data packages submitted to BGTD must contain, and it’s detailed enough that sponsors who prepared their IND packages under earlier FDA guidance may find meaningful gaps when they convert those packages for Canadian filing.

The CTA-to-NOC Pathway: Realistic Timelines

A clinical trial in Canada requires a Clinical Trial Application (CTA) — the Canadian equivalent of an IND — not an IND itself. The documents required are substantially similar, but the regulatory framework is distinct. Health Canada’s default review period is 30 days, after which the trial may proceed unless BGTD issues a clinical hold.

For early-phase cell and gene therapy studies, BGTD reviewers typically scrutinize three areas with particular care: the quality of the investigational medicinal product (IMP), including vector or cell characterization; the nonclinical safety package in light of ICH S6(R1) and ICH S12; and the site-specific safety monitoring plan, especially for gene therapies with potential immunogenicity concerns.

Once a clinical program is complete, sponsors file a New Drug Submission (NDS) for market authorization. Standard review targets sit at approximately 300 days for a priority NDS. Health Canada’s Priority Review Policy — which applies to products offering substantial improvement over existing therapy for serious or life-threatening conditions — can reduce that target to approximately 180 days. Given that most cell and gene therapy indications involve rare genetic disorders, hematologic malignancies, or other serious conditions, Priority Review eligibility should be evaluated at the pre-submission stage, not as an afterthought.

One program that sponsors frequently overlook: the Project Facilitation Agreement (PFA). A PFA allows sponsors to engage with BGTD reviewers during the review cycle to resolve scientific questions before a formal deficiency notice is issued. For a cell or gene therapy NDS — where the data package is complex, novel, and inherently multidisciplinary — a PFA can prevent the kind of major objection notice that adds six to twelve months to an already long timeline. The administrative overhead is real but modest compared to that risk.

GMP for Cell and Gene Therapy Manufacturing: Where Canadian Requirements Get Specific

The manufacturing requirements for cell and gene therapies under Canada GMP are more nuanced than the standard pharmaceutical GMP framework, and this is where sponsors most consistently underestimate their preparation burden.

Health Canada’s GMP expectations for biologics reference the principles of WHO GMP Annex 2 for biological products. For gene therapies involving viral vectors — lentiviral, AAV, adenoviral — biosafety classification of the manufacturing environment must be established and documented before GMP manufacturing begins. For most replication-incompetent viral vectors, this means Biosafety Level 2 (BSL-2) containment with specific validated procedures for inactivation of waste streams and documented personnel training records. BGTD reviewers will ask for this documentation as part of the CTA quality module, and gaps there have stalled programs.

Autologous cell therapies — where each lot is a single patient’s cells — present a structural problem for conventional batch release. You can’t quarantine a product for 14 days of compendial sterility testing when the product expires in approximately 72 hours. Health Canada’s approach here is pragmatic: rapid microbial methods validated per USP <1071> are acceptable, but the validation data must be filed with the CTA quality package. BGTD also expects ongoing correlation with traditional compendial results during development, with a bridging study package demonstrating equivalence before Phase 3 begins.

Allogeneic products bring a different set of challenges. Source material — donor-derived cells — is subject to Health Canada’s Safety of Human Cells, Tissues and Organs (CTO) Regulations for screening purposes. The master cell bank (MCB) characterization package must address identity, purity, sterility, adventitious agents, and mycoplasma testing in a manner consistent with ICH Q5A and ICH Q5D. And then there’s the potency question. BGTD expects a validated, mechanism-of-action-reflective potency assay by the time a Phase 3 trial begins. A surrogate assay may pass muster in Phase 1/2, but sponsors who haven’t invested in assay development early often find themselves forced into a Phase 3 delay while they catch up.

One more GMP item that catches sponsors off guard: analytical method transfer. If you’re moving manufacturing — even partially — between sites for the Canadian program, Health Canada’s GMP requirements for method transfer under Canada GMP apply. That means a documented transfer protocol, acceptance criteria, and a transfer validation report before the receiving site produces product for a Canadian trial. This isn’t optional, and it isn’t waived because the receiving site already holds a manufacturing authorization in another jurisdiction.

What Sponsors Moving From the US or EU Get Wrong

The most consistent error we see from sponsors entering Canada after completing US or EU development work is assuming that an FDA CBER IND package or an EMA IMPD converts cleanly into an acceptable CTA or NDS file. The scientific content is largely transferable. The regulatory architecture is not.

BGTD requires that manufacturing sites producing investigational products for Canadian clinical trials comply with Health Canada’s GMP — not merely FDA or EMA standards. In practice, Health Canada recognizes foreign inspection reports from jurisdictions that participate in the Pharmaceutical Inspection Co-operation Scheme (PIC/S), of which both the FDA and EMA are members. But “recognized” doesn’t mean “automatically accepted.” A foreign manufacturing site still needs to hold a valid Drug Establishment Licence (DEL) or be covered under a bilateral regulatory authority agreement, and BGTD will verify this at the CTA review stage — not later, when you assume all site qualification questions have been resolved.

A second gap that blindsides sponsors: bilingual labelling. English and French labelling is a legal requirement under the Food and Drug Regulations, including for clinical trial materials in most cases. Sponsors who discover this requirement after packaging investigational product face costly rework at minimum and, in some cases, program delays while reprinting and repackaging are arranged.

And a third: Health Canada does not have a formal Breakthrough Therapy Designation program equivalent to FDA’s. Sponsors who managed their FDA program around Breakthrough designation often find that the benefit of accelerated interactions they took for granted doesn’t translate directly into the Canadian review process. Priority Review is the closest equivalent, and it primarily affects review timelines — not the frequency or nature of sponsor-BGTD interactions during review.

Start With the Pre-Submission Meeting

If there’s one practical takeaway from all of the above, it’s this: before filing anything with BGTD for a cell or gene therapy program, request a pre-submission meeting. Health Canada typically schedules these within 60 days of a written request, and the scientific feedback is detailed enough to materially shape your submission strategy — which sections need more data, which nonclinical studies are essential versus supportive, and whether your proposed potency assay approach is likely to be accepted.

BGTD reviewers are knowledgeable and genuinely collaborative when sponsors come prepared with specific questions. That meeting is not a formality. For a program type where a single major objection notice can cost a year of review time, it’s one of the highest-return regulatory investments a Canadian sponsor can make.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Androxa. Learn more about our team

Talk to our team about Health Canada compliance for your cell or gene therapy program. Contact us

Related from our network

• Understanding FDA Biologics Regulation for US-Canada Cross-Border Programs — Qalitex Laboratories covers US GMP and FDA compliance requirements for biologic drug products seeking North American market access.
• EU Advanced Therapy Medicinal Products: The EMA Regulatory Framework Explained — Care Europe explores the EU’s ATMP regulatory pathway, including EMA Committee for Advanced Therapies (CAT) requirements and GMP for ATMPs under EU 1394/2007.